HC Wainwright Boosts uniQure (NASDAQ:QURE) Price Target to $70.00

uniQure (NASDAQ:QURE) had its price objective lifted by HC Wainwright from $25.00 to $70.00 in a research report sent to investors on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for uniQure’s Q4 2024 earnings at ($0.75) EPS, FY2024 earnings at ($4.17) EPS, Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($2.99) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at $6.91 EPS, FY2028 earnings at $16.97 EPS and FY2029 earnings at $18.47 EPS.

Several other analysts have also commented on the company. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. The Goldman Sachs Group increased their price target on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Leerink Partners raised their price target on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Wednesday, December 11th. Finally, Stifel Nicolaus boosted their target price on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $40.00.

uniQure Price Performance

QURE opened at $15.24 on Monday. The company has a market capitalization of $742.80 million, a price-to-earnings ratio of -3.07 and a beta of 0.41. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The business’s fifty day simple moving average is $13.31 and its 200-day simple moving average is $8.84.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. On average, equities research analysts anticipate that uniQure will post -3.74 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its stake in uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 969 shares in the last quarter. Sanders Morris Harris LLC increased its stake in uniQure by 50.0% during the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after purchasing an additional 34,034 shares during the period. FNY Investment Advisers LLC acquired a new stake in shares of uniQure during the fourth quarter worth about $88,000. Franklin Resources Inc. purchased a new position in shares of uniQure in the third quarter valued at approximately $7,360,000. Finally, Geode Capital Management LLC grew its holdings in shares of uniQure by 1.3% in the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after purchasing an additional 6,362 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.